Blockade of PD-1 or its ligand PD-L1, with the aim to enhance CD8+ T cell-mediated antitumoral immunity, resulted in good response rates in the Eμ-TCL1 mouse model of CLL [11, 12]. The gene discussed is CD8A; the disease is B-cell chronic lymphocytic leukemia.